Cipla gains post receiving EIR
Cipla has received an Establishment Inspection Report (EIR) following the inspection done by USFDA at the company's Kurkumbh facility.
The United States Food and Drug Administration (USFDA) conducted an inspection at the Kurkumbh manufacturing facility and the company received an EIR which marks the end of the inspection. The inspection was conducted from March 11, 2019 to March 20, 2019.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1,500 products across a wide range of therapeutic categories with one quality standard globally.
On Monday, the shares of Cipla opened at Rs. 565 against Friday’s close of Rs. 549. At closing hours, the stock was trading at Rs. 553.70, 0.75 per cent lower than the previous close on the BSE. It reached an intraday high of Rs. 565 and an intraday low of Rs. 550 per share on the BSE. The 52-week high stood at Rs. 678 and 52-week low was at Rs. 483 per share on the BSE.